top of page
Go Public Header.png

Will RenovoRx Become the Next Break Through Billion Dollar Cancer Treatment Therapy Company?

510(k) Device May Improve Targeted Delivery of Chemotherapy

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System.


LOS ALTOS, Calif., November 15, 2021--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2021.



*Approximate market cap as of 1/25/21

Investor Insight

Is localized treatment of cancer a game changing medical technology?
Does having a large reserve of cash for a biotech company make a investment in it more secure?
Will you be adding RenovoRx (Nasdaq: RNXT) to your watchlist?

Thanks for submitting!

Company Contact

4546 El Camino Real • Suite B1
Los Altos, CA 94022

Phone: (650) 284-4433
Fax: (650) 397-4433

Company Description

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform. RenovoTAMP delivers approved small molecule chemotherapeutic agents locally to the solid tumors. RenovoRx’s lead product candidate, RenovoGem™, uses intra-arterial delivery of gemcitabine, an approved chemotherapeutic agent, to treat unresectable locally advanced pancreatic cancer (LAPC) and is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.


RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.


RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

Want Exclusive Stock Reports?

Thanks for submitting!

Investment Platforms:

Group 831.png

SmallCap Trading recommends using to build your financial portfolio.

Leadership Team

Shaun R. Bagai

Chief Executive Officer

Over 21 years of medical technology expertise with a proven track record in leadership roles in clinical research, physician training, sales, marketing, and market development


Ramtin Agah, MD

Chief Medical Officer, Founder

Founder and the originator of the RenovoRx technology. Currently Interventional Cardiologist at El Camino Hospital, Mountain View.


Chris Lehman

Chief Financial Officer

Affiliated with LS Associates, Inc. which provides on-demand C-level executives. Pursuant to the contract between LS Associates, Inc. and RenovoRx, Mr. Lehman became Chief Financial Officer upon completion of the initial public offering.


Nicole Lama

Sr. Director, Clinical Operations and Research

Over 20 years of experience in pharmaceutical and medical device clinical research, on both the institution and sponsor sides.


Imtiaz Qureshi, MD

Director of Imaging

Went to Aga Khan University School of Medicine and graduated with honors. Currently at El Camino Hospital where he has been the Medical Director and Chief of Radiology for the last 10 years.

Legal Disclaimer

This website/media webpage is owned, operated, and edited by 154 Agency LLC. Any wording found on this website/media webpage or disclaimer referencing to “I” or “we” or “our” or “154 Agency” refers to 154 Agency LLC. This website/media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website/media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature. Therefore, we are unqualified to give investment recommendations. Always do your research and consult with a licensed investment professional before investing. This communication is not to be used as the foundation for making investment decisions and is for entertainment purposes only. This communication should serve only as a starting point of your research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose.
By using our service, you agree not to hold our site, or staff responsible for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website/media webpage. We do not advise any reader to take any specific action. Losses can be fatal if the company experiences any problems with liquidity or wide spreads. Our website/media webpage is for entertainment purposes only. Gains mentioned in our website/media webpage may be based on end-of-day or intraday data. Do not make an investment decision based on our alerts.
This publication, its owners, and affiliates may hold positions in the securities mentioned in our alerts; these may sell at any time without notice to our subscribers, which may hurt share prices.
154 Agency business model is to receive financial compensation to promote public companies. This includes, but is not limited to: conducting investor relations advertising, marketing, and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker 
Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased, and therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third-party, profiled company or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely to expand our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website/media webpage. The information in our website/media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, 154 Agency often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but there is always the possibility of errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all our communications is incorrect until you verify the information. We encourage you to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

bottom of page